Cadrenal Therapeutics files resale prospectus for up to 2.94M shares by selling stockholders

Filed July 20, 2026 · ~1 min read

Key Changes

• high

  The prospectus covers resale of up to 2,942,400 shares of common stock by selling stockholders, including shares underlying warrants from a July 2026 PIPE.

  The Offering verify on EDGAR →
• high

  This is a secondary offering; the company will not receive any proceeds from the sale of shares by the selling stockholders.

  The Offering verify on EDGAR →
• high

  The shares consist of 2,880,000 shares underlying pre-funded and common warrants issued to an investor in a private placement, and 62,400 shares underlying placement agent warrants.

  The Offering verify on EDGAR →